Diffuse Large B Cell Lymphoma Clinical Trials in Beijing, Beijing Municipality
13 recruitingBeijing, Beijing Municipality, China
Showing 1–13 of 13 trials
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled263 locationsNCT06717347
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled132 locationsNCT05139017
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Not Applicable
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Diffuse Large B Cell LymphomaRadiotherapyCAR-T+1 more
Peking Union Medical College Hospital20 enrolled1 locationNCT05514327
Recruiting
Glofitamab in Chinese Patients With R/R DLBCL
DLBCL - Diffuse Large B Cell Lymphoma
Peking Union Medical College Hospital20 enrolled1 locationNCT06481826
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 3
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.280 enrolled2 locationsNCT06929624
Recruiting
Phase 2
Pola-ZR2P in Previously Untreated DLBCL
Diffuse Large B Cell Lymphoma
Navy General Hospital, Beijing80 enrolled1 locationNCT06664411
Recruiting
Phase 1Phase 2
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Diffuse Large B Cell LymphomaAcute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in Relapse+4 more
Essen Biotech75 enrolled1 locationNCT06213636
Recruiting
Phase 2
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Diffuse Large B Cell Lymphoma
Navy General Hospital, Beijing240 enrolled1 locationNCT06503263
Recruiting
Phase 2
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Diffuse Large B Cell Lymphoma
Yan Zhang, MD30 enrolled1 locationNCT06176729
Recruiting
Phase 2
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma
Beijing Tongren Hospital100 enrolled1 locationNCT06081478
Recruiting
Frontline of ASCT in High-risk DLBCL
Diffuse Large B Cell Lymphoma
Peking University People's Hospital175 enrolled1 locationNCT05831865